Deng, Qing
Han, Guangchun http://orcid.org/0000-0001-9277-2507
Puebla-Osorio, Nahum http://orcid.org/0000-0001-6498-5230
Ma, Man Chun John http://orcid.org/0000-0002-2000-8144
Strati, Paolo http://orcid.org/0000-0002-7445-1459
Chasen, Beth
Dai, Enyu
Dang, Minghao
Jain, Neeraj http://orcid.org/0000-0002-3736-8621
Yang, Haopeng
Wang, Yuanxin
Zhang, Shaojun http://orcid.org/0000-0001-5760-5797
Wang, Ruiping
Chen, Runzhe
Showell, Jordan
Ghosh, Sreejoyee
Patchva, Sridevi
Zhang, Qi http://orcid.org/0000-0003-3813-8032
Sun, Ryan
Hagemeister, Frederick
Fayad, Luis
Samaniego, Felipe
Lee, Hans C.
Nastoupil, Loretta J. http://orcid.org/0000-0001-6071-8610
Fowler, Nathan
Eric Davis, R.
Westin, Jason
Neelapu, Sattva S. http://orcid.org/0000-0003-1045-4914
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Green, Michael R. http://orcid.org/0000-0001-6309-9472
Article History
Received: 14 September 2019
Accepted: 13 August 2020
First Online: 5 October 2020
Competing interests
: B.C. reports advisory board membership for Advanced Accelerator Application and Clovis Oncology. N.F. reports advisory board membership for Roche, BMS, Gilead and Novartis; research funding from Roche, BMS, Novartis and BostonGene; and employment from BostonGene. H.C.L. reports consulting fees from Adaptive Biotechnologies, Amgen, Celgene, GlaxoSmithKline, Janssen, Sanofi and Takeda Pharmaceuticals and research funding from Amgen, Celgene, Daiichi Sankyo, GlaxoSmithKline, Janssen, Regeneron and Takeda Pharmaceuticals. L.J.N. reports personal fees and research fees from Celgene, Genentech, Juno, Merck and TG Therapeutics and personal fees from Bayer, Novartis and Spectrum Pharmaceuticals. J.W. reports advisory board membership for Kite/Gilead, Juno/Celgene/BMS, Novartis, Genentech, Janssen, Amgen, AstraZeneca, Curis and Morphosys and research funding from Kite/Gilead, June/Celgene/BMS, Novartis, Genentech, Janssen, AstraZeneca, 47, Unum Therapeutics, Curis and Morphosys. S.S.N. has received research support from Kite/Gilead, Cellectis, Poseida, Merck, Acerta, Karus, BMS, Unum Therapeutics, Allogene and Precision Biosciences; has served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, Merck, Precision Biosciences, Cell Medica, Incyte, Allogene, Calibr and Legend Biotech; has received royalty income from Takeda Pharmaceuticals; and has patents related to cell therapy. M.R.G. reports consulting for VeraStem Oncology and stock ownership interest in KDAc Therapeutics.